TAMPA, Florida – TruPharma, LLC (TruPharma) announced today that pursuant to an agreement entered in October 2025, Saptalis Pharmaceuticals, LLC has engaged TruPharma to manage the day-to-day sales & marketing of its existing portfolio of more than ten FDA-approved ANDA products, as well as a pipeline of pending ANDA products.  TruPharma will support its existing US operation with the sales, marketing and distribution of these products on the Saptalis label.